SCOPUS 정보 검색 플랫폼

Lancet

Volumn 367, Issue 9517, 2006, Pages 1141-1142

The FIELD study

(1) Sirtori, Cesare R a

a OSPEDALE NIGUARDA CA GRANDA (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; RESIN; HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETES MELLITUS; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LETTER; MICROALBUMINURIA; PRIORITY JOURNAL; RETINOPATHY; RISK REDUCTION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK FACTOR; BLOOD; CHEMICALLY INDUCED DISORDER; VEIN THROMBOSIS;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; MORTALITY; PROCETOFEN; RISK FACTORS; HOMOCYSTEINE; VENOUS THROMBOSIS;

EID: 33645997380 PISSN: 01406736 EISSN: None Source Type: Journal
DOI: 10.1016/S0140-6736(06)68500-0 Document Type: Letter

Times cited : (4)

References (5)

1
- 28044452217
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
- The FIELD study investigators
- The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
- (2005) Lancet , vol.366 , pp. 1849-1861

2
- 28044443903
- After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
- Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet 366 (2005) 1829-1831
- (2005) Lancet , vol.366 , pp. 1829-1831
- Colhoun, H.¹

3
- 0037420492
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
- for the ASCOT investigators
- Sever P., Dahlöf B., Poulter N., et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
- (2003) Lancet , vol.361 , pp. 1149-1158
- Sever, P.¹ Dahlöf, B.² Poulter, N.³

4
- 20944448451
- Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA)
- Sever P., Poulter N., Dahlöf B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
- (2005) Diabetes Care , vol.28 , pp. 1151-1157
- Sever, P.¹ Poulter, N.² Dahlöf, B.³

5
- 0034283477
- Cardiovascular risk changes after lipid lowering medications: are they predictable?
- Sirtori C., Calabresi L., Marchioli R., and Rubins H. Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis 152 (2000) 1-8
- (2000) Atherosclerosis , vol.152 , pp. 1-8
- Sirtori, C.¹ Calabresi, L.² Marchioli, R.³ Rubins, H.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.